Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss

Jin Kanzaki, Yasuhiro Inoue, Kaoru Ogawa, Satoshi Fukuda, Kunihiro Fukushima, Kiyofumi Gyo, Naoaki Yanagihara, Tomoyuki Hoshino, Jun Ichi Ishitoya, Minoru Toriyama, Ken Kitamura, Kazuo Murai, Tsutomu Nakashima, Hideto Niwa, Yasuya Nomura, Hitome Kobayashi, Makoto Oda, Makito Okamoto, Tetuya Shitara, Masafumi Sakagami & 2 others Tetsuya Tono, Shin Ichi Usami

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalAuris Nasus Larynx
Volume30
Issue number2
DOIs
Publication statusPublished - 2003 May 15

Fingerprint

Sudden Hearing Loss
Sensorineural Hearing Loss
Hearing
beraprost
Pharmaceutical Preparations
Hearing Loss
Diatrizoate
Therapeutics
Betamethasone
Alprostadil
Ear
Hydrocortisone
Japan
Adenosine Triphosphate
Clinical Trials

Keywords

  • Idiopathic sudden sensori-neural hearing loss
  • Multi-center trial
  • Prognosis
  • Single drug treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Kanzaki, J., Inoue, Y., Ogawa, K., Fukuda, S., Fukushima, K., Gyo, K., ... Usami, S. I. (2003). Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. Auris Nasus Larynx, 30(2), 123-127. https://doi.org/10.1016/S0385-8146(03)00009-9

Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. / Kanzaki, Jin; Inoue, Yasuhiro; Ogawa, Kaoru; Fukuda, Satoshi; Fukushima, Kunihiro; Gyo, Kiyofumi; Yanagihara, Naoaki; Hoshino, Tomoyuki; Ishitoya, Jun Ichi; Toriyama, Minoru; Kitamura, Ken; Murai, Kazuo; Nakashima, Tsutomu; Niwa, Hideto; Nomura, Yasuya; Kobayashi, Hitome; Oda, Makoto; Okamoto, Makito; Shitara, Tetuya; Sakagami, Masafumi; Tono, Tetsuya; Usami, Shin Ichi.

In: Auris Nasus Larynx, Vol. 30, No. 2, 15.05.2003, p. 123-127.

Research output: Contribution to journalArticle

Kanzaki, J, Inoue, Y, Ogawa, K, Fukuda, S, Fukushima, K, Gyo, K, Yanagihara, N, Hoshino, T, Ishitoya, JI, Toriyama, M, Kitamura, K, Murai, K, Nakashima, T, Niwa, H, Nomura, Y, Kobayashi, H, Oda, M, Okamoto, M, Shitara, T, Sakagami, M, Tono, T & Usami, SI 2003, 'Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss', Auris Nasus Larynx, vol. 30, no. 2, pp. 123-127. https://doi.org/10.1016/S0385-8146(03)00009-9
Kanzaki, Jin ; Inoue, Yasuhiro ; Ogawa, Kaoru ; Fukuda, Satoshi ; Fukushima, Kunihiro ; Gyo, Kiyofumi ; Yanagihara, Naoaki ; Hoshino, Tomoyuki ; Ishitoya, Jun Ichi ; Toriyama, Minoru ; Kitamura, Ken ; Murai, Kazuo ; Nakashima, Tsutomu ; Niwa, Hideto ; Nomura, Yasuya ; Kobayashi, Hitome ; Oda, Makoto ; Okamoto, Makito ; Shitara, Tetuya ; Sakagami, Masafumi ; Tono, Tetsuya ; Usami, Shin Ichi. / Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. In: Auris Nasus Larynx. 2003 ; Vol. 30, No. 2. pp. 123-127.
@article{00d0082661e44cc69eee6f96c6e363a7,
title = "Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss",
abstract = "Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.",
keywords = "Idiopathic sudden sensori-neural hearing loss, Multi-center trial, Prognosis, Single drug treatment",
author = "Jin Kanzaki and Yasuhiro Inoue and Kaoru Ogawa and Satoshi Fukuda and Kunihiro Fukushima and Kiyofumi Gyo and Naoaki Yanagihara and Tomoyuki Hoshino and Ishitoya, {Jun Ichi} and Minoru Toriyama and Ken Kitamura and Kazuo Murai and Tsutomu Nakashima and Hideto Niwa and Yasuya Nomura and Hitome Kobayashi and Makoto Oda and Makito Okamoto and Tetuya Shitara and Masafumi Sakagami and Tetsuya Tono and Usami, {Shin Ichi}",
year = "2003",
month = "5",
day = "15",
doi = "10.1016/S0385-8146(03)00009-9",
language = "English",
volume = "30",
pages = "123--127",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss

AU - Kanzaki, Jin

AU - Inoue, Yasuhiro

AU - Ogawa, Kaoru

AU - Fukuda, Satoshi

AU - Fukushima, Kunihiro

AU - Gyo, Kiyofumi

AU - Yanagihara, Naoaki

AU - Hoshino, Tomoyuki

AU - Ishitoya, Jun Ichi

AU - Toriyama, Minoru

AU - Kitamura, Ken

AU - Murai, Kazuo

AU - Nakashima, Tsutomu

AU - Niwa, Hideto

AU - Nomura, Yasuya

AU - Kobayashi, Hitome

AU - Oda, Makoto

AU - Okamoto, Makito

AU - Shitara, Tetuya

AU - Sakagami, Masafumi

AU - Tono, Tetsuya

AU - Usami, Shin Ichi

PY - 2003/5/15

Y1 - 2003/5/15

N2 - Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.

AB - Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.

KW - Idiopathic sudden sensori-neural hearing loss

KW - Multi-center trial

KW - Prognosis

KW - Single drug treatment

UR - http://www.scopus.com/inward/record.url?scp=0037659382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037659382&partnerID=8YFLogxK

U2 - 10.1016/S0385-8146(03)00009-9

DO - 10.1016/S0385-8146(03)00009-9

M3 - Article

VL - 30

SP - 123

EP - 127

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 2

ER -